Mammalian Display offers a proprietary technology enabling the construction of massive libraries of stable cell lines displaying human antibodies on their surface. As well as generating an abundance of therapeutic antibody leads, the technology also addresses “developability” issues early in discovery, thereby increasing the likelihood of successful progress through the development process. The platform uses gene editing technology to efficiently direct site-specific integration of antibody genes into a single locus within the mammalian cell genome. This enables construction of libraries of tens of millions of monoclonal stable cell lines displaying IgG-formatted antibodies on their surface. Using flow cytometry many millions of clones can be screened directly for high affinity and specificity. The technology can also identify and avoid clones with potential biophysical liabilities which could otherwise lead to costly delays or even product failure. As well as antibody discovery programs, the technology is suitable to chain shuffling and affinity maturation allowing the identification of antibodies with high affinities and/or improved developability profiles.
FairJourney BiologicsSolutionsFairJourney Biologics is an established company with an outstanding track record of biotech and biopharmaceutical partners.Visit website
IONTASSolutionsIONTAS is a biotechnology company focussed on the development of novel antibody therapeutics using phage display and proprietary technology platforms.Visit website
Flow Eighteen38SolutionsFlow Eighteen38 offers bespoke protein production and characterization solutions to accelerate antibody projects.Visit website